Martin Unverdorben

Showing 1-3 of 3 articles

Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study

Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner G, Antoni D, Kleber F-X, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B

December 20, 2015 | 10.4244/EIJY14M08_12

Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months?

Unverdorben M, Kleber F-X, Heuer H, Figulla HR, Vallbracht C, Leschke M, Cremers B, Hardt S, Buerke M, Ackermann H, Boxberger M, Degenhardt R, Scheller B

September 27, 2013 | 10.4244/EIJV9I5A99

Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus

Ali R, Degenhardt R, Zambahari R, Tresukosol D, Ahmad W, bin Haron Kamar H, Kui-Hian S, Ong T, bin Ismail O, bin Elis S, Udychalerm W, Ackermann H, Boxberger M, Unverdorben M

May 17, 2011

1

Latest news

EAPCI/ACVC consensus on pVADs, coronary physiology mini focus, a new analysis from the COAPT trial, patient selection for tricuspid interventions and more…

Treatment of secondary mitral regurgitation in patients with heart failure

Marco Metra et al

This Week's JAA's: Principles and Pitfalls in CFT, Brachial access for PCI....

Coronary flow capacity: where to next?

Nils P. Johnson

Joint EAPCI/ACVC expert consensus document on pVADs

EuroIntervention's new impact factor!

STATE OF THE ART

Completeness of Revascularisation in ACS Patients with Multivessel Disease

Valeria Paradies et al.

Valvular disease